Kaleido

Mahalo Health is a unified digital health platform designed to accelerate the development of patient-centric digital health applications and clinical trials. By offering prebuilt modules. Mahalo enables rapid deployment of white-label apps tailored to specific therapeutic areas. The platform's unified data capabilities include a predictive health engine for disease prediction and diagnosis, a behavior change engine to promote positive patient actions, and a notification engine for timely communications via push, SMS, or email. Ensuring robust security and compliance, Mahalo adheres to standards like HIPAA, GCP, ISO27001, and GDPR. Its services span various therapeutic areas, including diabetes, cognitive health, cardiovascular conditions, musculoskeletal disorders, mental health, oncology, rare diseases, and nonalcoholic steatohepatitis (NASH).

Specialty and rare diseases have undefined patient populations, with individuals who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as treatment journeys that are not well understood. IPM.ai is an Insights-as-a-Service (IaaS) company that empowers the world’s leading life sciences brands to better understand and improve the lives of patients through the development, clinical study, and commercialization of therapeutic interventions. Maximize commercialization efforts by forecasting market size, competitive landscape, and potential ROI. Uncover ideal patients who are undiagnosed and/or misdiagnosed who may be appropriate for disease interception and therapeutic intervention. Statistically model the number of disease cases present in a particular patient population at a given time. Identify physicians who diagnose and treat ideal patients and influence other health care providers.